These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32563288)

  • 21. The biochemical bases of the placebo effect.
    de la Fuente-Fernández R; Stoessl AJ
    Sci Eng Ethics; 2004 Jan; 10(1):143-50. PubMed ID: 14986780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of the thalamic-subthalamic circuit involved in the placebo response through single-neuron recording in Parkinson patients.
    Frisaldi E; Carlino E; Lanotte M; Lopiano L; Benedetti F
    Cortex; 2014 Nov; 60():3-9. PubMed ID: 24457096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nigrostriatal and Mesolimbic D
    Stark AJ; Smith CT; Lin YC; Petersen KJ; Trujillo P; van Wouwe NC; Kang H; Donahue MJ; Kessler RM; Zald DH; Claassen DO
    J Neurosci; 2018 Mar; 38(13):3230-3239. PubMed ID: 29483278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Motor and cognitive placebo-/nocebo-responses in Parkinson's disease patients with deep brain stimulation.
    Keitel A; Wojtecki L; Hirschmann J; Hartmann CJ; Ferrea S; Südmeyer M; Schnitzler A
    Behav Brain Res; 2013 Aug; 250():199-205. PubMed ID: 23651878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Greater striatal responses to medication in Parkinson׳s disease are associated with better task-switching but worse reward performance.
    Aarts E; Nusselein AA; Smittenaar P; Helmich RC; Bloem BR; Cools R
    Neuropsychologia; 2014 Sep; 62():390-7. PubMed ID: 24912070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice.
    Mestre TA; Shamy M; Benedetti F; Lang AE
    Mov Disord; 2018 Aug; 33(8):1195-1203. PubMed ID: 30145820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immediate placebo effect in Parkinson's disease--is the subjective relief accompanied by objective improvement?
    Fregni F; Boggio PS; Bermpohl F; Maia F; Rigonatti SP; Barbosa ER; Pascual-Leone A
    Eur Neurol; 2006; 56(4):222-9. PubMed ID: 17057382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies.
    Diederich NJ; Goetz CG
    Neurology; 2008 Aug; 71(9):677-84. PubMed ID: 18725593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determinants of placebo effects.
    Anderson S; Stebbins GT
    Int Rev Neurobiol; 2020; 153():27-47. PubMed ID: 32563291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What influences placebo and nocebo responses in Parkinson's disease?
    Witek N; Stebbins GT; Goetz CG
    Mov Disord; 2018 Aug; 33(8):1204-1212. PubMed ID: 30132980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Habitual exercisers versus sedentary subjects with Parkinson's Disease: Multimodal PET and fMRI study.
    Sacheli MA; Murray DK; Vafai N; Cherkasova MV; Dinelle K; Shahinfard E; Neilson N; McKenzie J; Schulzer M; Appel-Cresswell S; McKeown MJ; Sossi V; Jon Stoessl A
    Mov Disord; 2018 Dec; 33(12):1945-1950. PubMed ID: 30376184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Would the elderly be better off if they were given more placebos?
    Cherniack EP
    Geriatr Gerontol Int; 2010 Apr; 10(2):131-7. PubMed ID: 20100289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ventral striatal network connectivity reflects reward learning and behavior in patients with Parkinson's disease.
    Petersen K; Van Wouwe N; Stark A; Lin YC; Kang H; Trujillo-Diaz P; Kessler R; Zald D; Donahue MJ; Claassen DO
    Hum Brain Mapp; 2018 Jan; 39(1):509-521. PubMed ID: 29086460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of intravenous placebo with glucose expectation on human basal ganglia dopaminergic function.
    Haltia LT; Rinne JO; Helin S; Parkkola R; Någren K; Kaasinen V
    Synapse; 2008 Sep; 62(9):682-8. PubMed ID: 18566972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson's disease: a detailed PET analysis of 12 striatal subregions.
    Park SB; Kwon KY; Lee JY; Im K; Sunwoo JS; Lee KB; Roh H; Ahn MY; Park S; Kim SJ; Oh JS; Kim JS
    Neurol Sci; 2019 Feb; 40(2):311-317. PubMed ID: 30415448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Levodopa impairs probabilistic reversal learning in healthy young adults.
    Vo A; Seergobin KN; Morrow SA; MacDonald PA
    Psychopharmacology (Berl); 2016 Jul; 233(14):2753-63. PubMed ID: 27241710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine modulates striatal response to reward and punishment in patients with Parkinson's disease: a pharmacological challenge fMRI study.
    Argyelan M; Herzallah M; Sako W; DeLucia I; Sarpal D; Vo A; Fitzpatrick T; Moustafa AA; Eidelberg D; Gluck M
    Neuroreport; 2018 May; 29(7):532-540. PubMed ID: 29432300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.